Диссертация (Прогнозирование метаболитов рилизинг-пептидов гормона роста в организме человека для разработки методики их определения в целях антидопингового контроля), страница 23

Howard, S.D. Feighner, D.F. Cully, J.P. Arena,138P.A. Liberator, C.I. Rosenblum, M. Hamelin, D.L. Hreniuk, O.C. Palyha, J. Anderson,P.S. Paress, C. Diaz, M. Chou, K.K. Liu, K.K. McKee, S.S. Pong, L.Y. Chaung, A.Elbrecht, M. Dashkevicz, R. Heavens, M. Rigby, D.J. Sirinathsinghji, D.C. Dean, D.G.Melillo, A.A. Patchett, R. Nargund, P.R. Griffin, J.A. DeMartino, S.K. Gupta, J.M.Schaeffer, R.G. Smith, L.H. Van der Ploeg // Sci. — 1996.

— Vol. 273. — No 5277. —P. 974—977.32)Dean, D.C. Development of a high specific activity sulfur-35-labeledsulfonamide radioligand that allowed the identification of a new growth hormonesecretagogue receptor [Text] / D.C. Dean, R.P. Nargund, S.S. Pong, L.Y. Chaung, P.Griffin, D.G. Melillo, R.L. Ellsworth, L.H. Van der Ploeg, A.A.

Patchett, R.G. Smith //J. Med. Chem. — 1996. — Vol. 39. — No 9. — P. 1767—1770.33)Pong, S.S. Identification of a new G-protein-linked receptor for growthhormone secretagogues [Text] / S.S. Pong, L.Y. Chaung, D.C. Dean, R.P. Nargund,A.A. Patchett, R.G. Smith // Mol. Endocrinol. — 1996. — Vol. 10. — No 1. — P. 57—61.34)McKee, K.K. Molecular analysis of rat pituitary and hypothalamic growthhormone secretagogue receptors [Text] / K.K.

McKee, O.C. Palyha, S.D. Feighner, D.L.Hreniuk, C.P. Tan, M.S. Phillips, R.G. Smith, L.H. Van der Ploeg, A.D. Howard // Mol.Endocrinol. — 1997. — Vol. 11. — No 4. — P. 415—423.35)Yin, Y. The growth hormone secretagogue receptor: its intracellularsignaling and regulation [Text] / Y. Yin, Y. Li, W. Zhang // Int. J. Mol. Sci. — 2014. —Vol. 15.

— No 3. — P. 4837—4855.36)Isidro, M. Growth hormone secretagogues [Text] / M. Isidro, F. Cordido //Comb. Chem. High Throughput Screen. — 2006. — Vol. 9. — No 3. — P. 175—180.37)Kojima, M. Ghrelin is a growth-hormone-releasing acylated peptide fromstomach [Text] / M. Kojima, H. Hosoda, Y. Date, M. Nakazato, H.

Matsuo, K.Kangawa // Nature. — 1999. — Vol. 402. — No 6762. — P. 656—660.38)Hosoda, H. Biological, physiological, and pharmacological aspects ofghrelin [Text] / H. Hosoda, M. Kojima, K. Kangawa // J. Pharmacol. Sci. — 2006. —Vol. 100. — No 5. — P. 398—410.13939)Laron, Z. Growth hormone secretagogues. Clinical experience andtherapeutic potential [Text] / Z. Laron // Drugs. — 1995. — Vol. 50.

— No 4. —P. 595—601.40)Camanni, F. Growth hormone-releasing peptides and their analogs [Text] /F. Camanni, E. Ghigo, E. Arvat // Front. Neuroendocrinol. — 1998. — Vol. 19. —No 1. — P. 47—72.41)Di, L. Strategic approaches to optimizing peptide ADME properties [Text]/ L. Di // AAPS J. — 2015. — Vol. 17. — No 1. — P. 134—143.42)Mitchell, M.D.

Peptide-based in vitro assay for the detection of reactivemetabolites [Text] / M.D. Mitchell, M.M. Elrick, J.L. Walgren, R.A. Mueller, D.L.Morris, D.C. Thompson // Chem. Res. Toxicol. — 2008. — Vol. 21. — No 4. —P. 859—868.43)PeptideCutter tool. [Электронный ресурс] // ExPASy. Bioinformaticresourceportal:[сайт]:—http://web.expasy.org/peptide_cutter/peptidecutter_enzymes.html.URL:Датаобращения29.02.2016.44)Markert, Y. Proline versus charge concept for protein stabilization againstproteolytic attack [Text] / Y. Markert, J. Koditz, R. Ulbrich-Hofmann, U. Arnold //Protein Eng. — 2003.

— Vol. 16. — No 12. — P. 1041—1046.45)Sharma, R. In vitro metabolism of the glucagon-like peptide-1 (GLP-1)-derived metabolites GLP-1(9-36)amide and GLP-1(28-36)amide in mouse and humanhepatocytes [Text] / R. Sharma, T.S. McDonald, H. Eng, C. Limberakis, B.D. Stevens,S. Patel, A.S. Kalgutkar // Drug Metab. Dispos.

— 2013. — Vol. 41. — No 12. —P. 2148—2157.46)Martin, R.A. Dipeptidyl peptidase IV (DPP-IV) from pig kidney cleavesanalogs of bovine growth hormone-releasing factor (bGRF) modified at position 2 withSer, Thr or Val. Extended DPP-IV substrate specificity? [Text] / R.A. Martin, D.L.Cleary, D.M. Guido, H.A. Zurcher-Neely, T.M. Kubiak // Biochim. Biophys. Acta. —1993.

— Vol. 1164. — No 3. — P. 252—260.14047)Grossman, T.H. Spontaneous cAMP-dependent derepression of geneexpression in stationary phase plays a role in recombinant expression instability [Text] /T.H. Grossman, E.S. Kawasaki, S.R. Punreddy, M.S. Osburne // Gene. — 1998. —Vol. 209. — No 1—2. — P. 95—103.48)Bercu, B.B. Growth hormone secretagogues [Text] / B.B. Bercu, R.F.Walker // New-York.: Springer. — 1996. — P. 416.49)Kubiak, T.M. Position 2 and position 2/Ala15-substituted analogs ofbovine growth hormone-releasing factor (bGRF) with enhanced metabolic stability andimproved in vivo bioactivity [Text] / T.M. Kubiak, A.R. Friedman, R.A. Martin, A.K.Ichhpurani, G.R.

Alaniz, W.H. Claflin, M.C. Goodwin, D.L. Cleary, C.R. Kelly, R.M.Hillman, R.T. Downs, L.A. Frochman, W.M. Moseley // J. Med. Chem. — 1993. —Vol. 36. — No 7. — P. 888—897.50)Ogasahara, K. Effect of single amino acid substitutions on the proteasesusceptibility of tryptophan synthase alpha subunit [Text] / K. Ogasahara,S. Tsunasawa, Y. Soda, K. Yutani, Y. Sugino // Eur. J. Biochem.

— 1985. — Vol. 150.— No 1. — P. 17—21.51)Yutani, K. Effect of amino acid substitutions on conformational stability ofa protein [Text] / K. Yutani, K. Ogasahara, Y. Sugino // Adv. Biophys. — 1985. —Vol. 20. — P. 13—29.52)Bolli, G.B. Insulin analogues and their potential in the management ofdiabetes mellitus [Text] / G.B. Bolli, R.D. Di Marchi, G.D. Park, S. Pramming, V.A.Koivisto // Diabetologia.

— 1999. — Vol. 42. — No 10. — P. 1151—1167.53)Noble, S.L. Insulin Lispro: A Fast-Acting Insulin Analog [Text] / S.L.Noble, E. Johnston, B. Walton // Am. Fam. Physician. — 1998. — Vol. 57. — No 2. —P. 279—286.54)Ollivaux, C. Biogenesis of D-amino acid containing peptides/proteins:where, when and how? [Text] / C. Ollivaux, D. Soyez, J.Y. Toullec // J. Pept. Sci. —2014.

— Vol. 20. — No 8. — P. 595—612.55)Panatier, A. Glia-derived D-serine controls NMDA receptor activity andsynaptic memory [Text] / A. Panatier, D.T. Theodosis, J.P. Mothet, B. Touquet, L.141Pollegioni, D.A. Poulain, S.H. Oliet // Cell. — 2006. — Vol. 125. — No 4. — P. 775—784.56)Huang, A.S. D-aspartate regulates melanocortin formation and function:behavioral alterations in D-aspartate oxidase-deficient mice [Text] / A.S.

Huang, A.Beigneux, Z.M. Weil, P.M. Kim, M.E. Molliver, S. Blackshaw, R.J. Nelson, S.G.Young, S.H. Snyder // J. Neurosci. — 2006. — Vol. 26. — No 12. — P. 2814—2819.57)Белки против РНК — кто первым придумал сплайсинг? [Электронныйресурс] // Биомолекула.ру : [сайт]: — URL: http://biomolecula.ru/content/199/. Датаобращения: 15.04.2016.58)Gentilucci, L. Chemical modifications designed to improve peptidestability: incorporation of non-natural amino acids, pseudo-peptide bonds, andcyclization [Text] / L. Gentilucci, R. De Marco, L. Cerisoli // Curr. Pharm.

Des. —2010. — Vol. 16. — No 28. — P. 3185—3203.59)Matuszewska, B. In vitro study of intestinal absorption and metabolism of8-l-arginine vasopressin and its analogues [Text] / B. Matuszewska, G.G. Liversidge, F.Ryan, J. Dent, P.L. Smith // Int. J. Pharm. — 1988. — Vol. 46. — No 1—2. —P. 111—120.60)Fjellestad-Paulsen, A. Metabolism of vasopressin, oxytocin, and theiranalogues in the human gastrointestinal tract [Text] / A. Fjellestad-Paulsen, C.Söderberg-Ahlm, S. Lundin // Peptides. — 1995. — Vol. 16.

— No 6. — P. 1141—1147.61)Fjellestad-Paulsen, A. Metabolism of vasopressin, oxytocin and theiranalogues [Mpa1, D-Arg8]-vasopressin (dDAVP) and [Mpa1, D-Tyr(Et)2, Thr4, Orn8]oxytocin (antocin) in human kidney and liver homogenates [Text] / A. FjellestadPaulsen, S. Lundin // Regul. Pept. — 1996. — Vol. 67. — No 1. — P. 27—32.62)Pressinoic acid (ab142354). [Электронный ресурс] // ABCAM : [сайт]:— URL: http://www.abcam.com/pressinoic-acid-ab142354.html. Дата обращения:21.02.2016.14263)Diao,L.Pharmacokineticsandpharmacokinetic-pharmacodynamiccorrelations of therapeutic peptides [Text] / L. Diao, B.

Meibohm // Clin.Pharmacokinet. — 2013. — Vol. 52. — No 12. — P. 855—868.64)Kjolbye, A.L. Pharmacological modulation of gap junction function withthe novel compound rotigaptide: a promising new principle for prevention ofarrhythmias [Text] / A.L. Kjolbye, K. Haugan, J.K. Hennan, J.S. Petersen // Basic Clin.Pharmacol. Toxicol. — 2007.

— Vol. 101. — No 4. — P. 215—230.65)Kjolbye, A.L. Pharmacological characterization of the new stableantiarrhythmic peptide analog Ac-D-Tyr-D-Pro-D-Hyp-Gly-D-Ala-Gly-NH2 (ZP123):in vivo and in vitro studies [Text] / A.L. Kjolbye, C.B. Knudsen, T. Jepsen, B.D.Larsen, J.S. Petersen // J. Pharmacol. Exp. Ther. — 2003. — Vol. 306. — No 3. —P. 1191—1199.66)Rafferty, B. Pharmacokinetic evaluation of superactive analogues ofgrowth hormone-releasing factor (1-29)-amide [Text] / B. Rafferty, D.H. Coy, S. Poole// Peptides. — 1988. — Vol.

9. — No 1. — P. 207—209.67)Darlak, K. Dermorphin analogs: resistance to in vitro enzymaticdegradation is not always increased by additional D-amino acid substitutions [Text] / K.Darlak, D.E. Benovitz, A.F. Spatola, Z. Grzonka // Biochem. Biophys. Res. Commun.— 1988. — Vol. 156. — No 1. — P. 125—130.68)Aguilar,M.-I.Beta-aminoacid-containinghybridpeptides--newopportunities in peptidomimetics [Text] / M.-I. Aguilar, A.W. Purcell, R. Devi, R. Lew,J. Rossjohn, A.I. Smith, P. Perimutter // Org.